Eton Pharmaceuticals, Inc. (ETON)
31.01
+0.48
(+1.57%)
USD |
NASDAQ |
Jun 10, 16:00
31.01
0.00 (0.00%)
After-Hours: 16:43
Eton Pharmaceuticals Enterprise Value : 846.90M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 846.90M |
| June 08, 2026 | 831.03M |
| June 05, 2026 | 808.59M |
| June 04, 2026 | 802.30M |
| June 03, 2026 | 767.01M |
| June 02, 2026 | 761.26M |
| June 01, 2026 | 796.28M |
| May 29, 2026 | 844.71M |
| May 28, 2026 | 883.28M |
| May 27, 2026 | 899.11M |
| May 26, 2026 | 868.71M |
| May 22, 2026 | 904.32M |
| May 21, 2026 | 970.34M |
| May 20, 2026 | 955.27M |
| May 19, 2026 | 912.54M |
| May 18, 2026 | 901.58M |
| May 15, 2026 | 840.50M |
| May 14, 2026 | 832.28M |
| May 13, 2026 | 855.83M |
| May 12, 2026 | 825.43M |
| May 11, 2026 | 828.02M |
| May 08, 2026 | 822.82M |
| May 07, 2026 | 860.30M |
| May 06, 2026 | 836.50M |
| May 05, 2026 | 842.79M |
| Date | Value |
|---|---|
| May 04, 2026 | 836.77M |
| May 01, 2026 | 802.30M |
| April 30, 2026 | 671.52M |
| April 29, 2026 | 656.75M |
| April 28, 2026 | 672.61M |
| April 27, 2026 | 653.19M |
| April 24, 2026 | 641.42M |
| April 23, 2026 | 640.06M |
| April 22, 2026 | 657.57M |
| April 21, 2026 | 655.65M |
| April 20, 2026 | 703.26M |
| April 17, 2026 | 696.69M |
| April 16, 2026 | 680.00M |
| April 15, 2026 | 749.49M |
| April 14, 2026 | 753.60M |
| April 13, 2026 | 724.32M |
| April 10, 2026 | 732.81M |
| April 09, 2026 | 753.05M |
| April 08, 2026 | 733.76M |
| April 07, 2026 | 697.24M |
| April 06, 2026 | 695.60M |
| April 02, 2026 | 695.32M |
| April 01, 2026 | 705.45M |
| March 31, 2026 | 686.84M |
| March 30, 2026 | 621.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Daré Bioscience, Inc. | 16.62M |
| Tarsus Pharmaceuticals, Inc. | 2.348B |
| ANI Pharmaceuticals, Inc. | 2.146B |
| Corcept Therapeutics, Inc. | 7.988B |
| Assertio Holdings, Inc. | 119.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.554M |
| Revenue (Quarterly) | 24.27M |
| Total Expenses (Quarterly) | 22.71M |
| EPS Diluted (Quarterly) | 0.0493 |
| Gross Profit Margin (Quarterly) | 60.72% |
| Profit Margin (Quarterly) | 6.40% |
| Earnings Yield | -0.23% |
| Operating Earnings Yield | 0.25% |
| Normalized Earnings Yield | -0.2073 |